Pharmaceutical

Rani reports positive data for non-injectable Stelara biosimilar

RT-111 could offer an alternative dosing regimen for patients with psoriasis and other conditions compared to injectable biologics.

Feb 6, 2024 - 18:00
Rani reports positive data for non-injectable Stelara biosimilar
RT-111 could offer an alternative dosing regimen for patients with psoriasis and other conditions compared to injectable biologics.
Read the original article

Tags:

Previous Article

Juul spent big to court Black leaders to promote its e-cigarettes, new documents...

Next Article

Novartis eyes $2.9bn MorphoSys buyout to expand oncology pipeline

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

The ‘Hispanic Paradox’ intrigues a new generation of researchers determined to unravel it

The ‘Hispanic Paradox’ intrigues a new generation of re...

Sep 14, 2023

STAT+: FDA’s Peter Marks seems inclined to grant full approval to Sarepta’s Duchenne gene therapy

STAT+: FDA’s Peter Marks seems inclined to grant full a...

Jan 10, 2024

Pfizer and Astellas seek updated EMA approval for Padcev with Keytruda

Pfizer and Astellas seek updated EMA approval for Padce...

Jan 29, 2024